This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Incyte's Management Presents At Goldman Sachs Healthcare Conference (Transcript)

Stocks in this article: INCY

Pat Andrews

So many of you have seen prior data on this particular compound as well as 424 and the data across RA patients has been very consistent. It’s a very potent JAK inhibitor; has a competitive profile and obviously looks very comparable to the data that’s been presented by Pfizer for tofacitinib. Our numbers are much smaller obviously so it’s early on. But it looks very promising it’s very encouraging; the data we presented on Friday in the late breaker session at ULR and then we hope later this year to show the six months data with Lilly, hopefully at ACR. And the next step would be to initiate the Phase III program and we also expect that to happen this year.

Pam Murphy

Maybe just flashing out some of the details, I mean clearly the efficacy side it seems that it is on the higher end of the ACR presented etcetera; on the appropriate doses it may look a little better than tofa at least in these early patients effects. On the same side, on the safety side I mean it seems like we saw a couple of things that we haven’t seen before like the creatinine increase on the drug. And so just want to get your thoughts of like you know do you think it’s possible to differentiate from tofa, from this week, like where do you think the differentiations will be eventually in the marketplace as the data holds out?

Pat Andrews

So I think that there will be a number of places that the products could differentiate; it’s a little bit difficult to say what all of them would be now, because they finished the Phase III and while we’ve seen quite a bit of data, we just have the Phase II data with a smaller number of patients. But some things that come to mind are very obvious such as 050 is a once-a-day drug versus tofa is a twice-a-day drug and 050 seems to not have many drug-to-drug interactions versus tofa had some and we have benefit from seeing the questions raised during the AdCom for tofa and there are some learnings from that that we could take in the design of the Phase III that should start later this year.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs